From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two
cSLE: n = 101 | SLE n = 37 | p* | |
---|---|---|---|
Ethnicity | |||
White | 71% | 68% | |
Non White (%) | 29% | 32% | |
Age at study visit (median (range)) | 33 (18 – 65)* | 38 (25 – 76)* | 0.003 |
Age at diagnosis in yrs (median (range)) | 14 (5 – 17)* | 26 (18 – 63)* | 0.000 |
Disease duration in yrs (median (range)) | 20 (1 – 55) | 12 (1 – 34) | 0.000 |
Current SLEDAI-2 K score (median (range)) | 4 (0 – 14) | 5 (0 – 10) | |
SDI-score (median (range)) | 1 (0 – 8) | 1 (0 – 7) | |
Patients with SLICC-DI ≥ 1 | 60% (61/40) | 57% (21/37) | |
cSLE restrictive in pregnancy wish | 66% (63/96) | 69% (25/36) | |
Patients ever pregnant (after diagnosis of SLE) | 36% (36/101) | 41% (9/22) | |
With history of cyclophosphamide use | 22% (8/36) | 22% (2/9) | |
Time to first pregnancy, months (median(range)) | 2 (0 – 84) | 1 (0 – 12) | n.s. |
Age at first pregnancy, yrs (median(range)) | 27 (18 – 36) | 30 (22 – 32) | n.s. |
Total number of pregnancies | 85 | 19 | |
Miscarriages (<20 weeks) | 15% (13/85) | 21% (4/19) | |
Induced Abortion | 6% (5/85) | 0 | |
Any pregnancy complications > 20 weeks | 37% (25/67) | 27% (4/15) | n.s. |
Stillbirth | 16% (4/25) | 0 | |
Pregnancy induced hypertension | 12% (3/25) | 0 | |
Pre-eclampsia/HELLP | 24% (6/25) | 0 | |
Preterm birth (AD < 37 weeks) | 20% (5/25) | 25% (1/4) | |
Median gestational age (range) | 31 wk,28-35 | 32 wk | |
Placental abruption | 8% (2/25) | 25% (1/4) | |
Other | 20% (5/25) | 50% (2/4) |